Development of a novel drug for the treatment of patients with glycolytic cancers

Offentlig prosjektsammendrag

Arctic Pharma´s overall goal is to bring a new class of cancer medicine to the market which targets the energy metabolism of many aggressive cancer types without generating strong side-effects. Since medication currently is often limited for these cancer types with high-relapse rate and consequently deadly outcome, we believe that our drug will have a major impact on healthcare and society. This project will advance an innovative chemical lead into a drug candidate, ready for clinical phase I studies. We will in parallel develop a tool to identify the right patients to be treated.